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studies in post-MI patients were positive is that the studies did not
adequately control for confounding variables is also open to
criticism. The fact that controlling for one variable eliminates the
significance of a second one does not necessarily mean that the
second factor is unimportant, because it may operate through the
first one. Thus, it is conceivable that if we had very good measures
of the extent of atherosclerotic plaque, the role of blood cholesterol
in causing MI would be “controlled for” by the plaque burden.
Would this lead us to conclude that cholesterol is not a risk factor?
Clearly, the issue here is which comes first; that is why the
prospective studies of disease-free subjects are so important.
What the depression–heart disease hypothesis sorely needs in
order to become established or refuted are more observational and
interventional studies. In addition to coronary artery disease
severity, variations in patient populations and differences in when
and how depression was assessed have been other explanations for
why some depression–heart disease studies have been negative.
We should not forget that many of the early intervention studies
attempting to test the lipid–heart disease hypothesis were negative.
To date, ENRICHD is the only published study that attempted to
reduce recurrence rates by treating depression, and its negative
results may well be due to an inadequate treatment effect, as was
observed with the lipid-lowering arm of ALLHAT (3).
Thomas G. Pickering, MD, DPhil
Karina Davidson, PhD
Daichi Shimbo, MD
Columbia Presbyterian Medical Center
PH 9-946
622 West 168 St.
New York, NY 10032
E-mail: tp2114@columbia.edu
doi:10.1016/j.jacc.2004.04.029
REFERENCES
1. Lane D, Carroll D, Lip GYH. Anxiety, depression, and prognosis after
myocardial infarction: is there a causal association? J Am Coll Cardiol
2003;42:1808–10.
2. Wulsin LR, Singal BM. Do depressive symptoms increase the risk for
the onset of coronary disease? A systematic quantitative review. Psy-
chosom Med 2003;65:201–10.
3. Major outcomes in moderately hypercholesterolemic hypertensive
patients randomized to pravastatin vs usual care: the Antihyperten-
sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT-LLT). JAMA 2002;288:2998 –3007.
REPLY
We welcome rejoinders to our editorial (1) by Carney et al. and
Pickering et al. The precise nature of the association between
depression and cardiac mortality in myocardial infarction (MI)
patients and, in particular, whether it is a causal association, is
an important public health matter; thus, we are grateful that our
arguments have sparked debate. However, there appear to be a
number of misconceptions in these responses as to our purpose
in writing the editorial and, indeed, in what we were trying to
say.
Pickering and colleagues accuse us of being “inappropriately
pessimistic.” This they ascribe to our failure to consider prospective
observational studies of depression in participants initially free of
cardiac disease, focusing instead solely on studies of depression
(and anxiety) in MI patients. The results from the latter, they
readily concede, afford a “weak” case for a causal association
between depression and cardiac mortality. Studies in initially
disease-free populations were simply beyond the scope of our
editorial and the brief given us. We would agree with Pickering et
al. that the data from such studies are somewhat more persuasive
(2). We would, however, make two points here. First, there are
sufficient instances where risk factors for mortality vary between
disease-free and diseased populations to suggest that caution is
warranted in generalizing from one to the other. Second, con-
founding cannot be summarily dismissed as a possible explanation
of the association between depression and cardiac mortality in
studies of initially disease-free participants; confounding always
has to be considered as a potential explanation in observational
epidemiological research (3). We also appreciate that it can be
difficult on occasion to distinguish between confounders and
mediators. This is one of the reasons why experimental evidence is
so critical (4). What we are arguing is that the data to date do not
preclude the possibility that depression after MI may not be a
cause, however mediated, of cardiac mortality, and for the reasons
articulated above, it is not at all clear to us how prospective
observational studies in initially disease-free populations will help
resolve this issue.
Furthermore, we were not asserting, as Carney et al. seem to
suggest, that depression is not an identified risk factor for cardiac
mortality after MI. What we are questioning, as we had hoped that
we had made plain, is whether depression is an independent risk
factor (i.e., a fundamental cause of cardiac mortality) so that
successful intervention for depression would improve survival after
MI. Based on the available evidence at this juncture, particularly
the results of the ENRICHD study, the one substantial published
randomized controlled trial (RCT) (5), it seems to us that the
parsimonious conclusion is that the independence of depression
still remains to be established. Moreover, we would submit these
null results from ENRICHD should cause us to pause and
consider alternative explanations for the pattern of results that have
emerged from observational epidemiological studies.
Carney et al. argue that the equivalence of outcome in the
ENRICHD trial between the intervention and usual care groups
most likely reflected the modest, albeit statistically significant,
between-group differences in depression post-intervention, and
they chide us as to whether we would dismiss cholesterol as a risk
factor on the basis of an ineffectual cholesterol-lowering drug.
Clearly we would not: but this is because there is now strong
experimental evidence from elsewhere implicating cholesterol (e.g.,
6). However, there was a time earlier in the history of cholesterol
research when the risk status of cholesterol was controversial and it
was perfectly appropriate to be skeptical (7). Likewise, we would be
among the first to shift our position on the nature of depression as
a risk for mortality after MI were positive experimental data to
become available. We have addressed the interpretation by Carney
et al. of the results of the ENRICHD ancillary study elsewhere (8).
Here we would simply make the point that correlational and
experimental data are not evidentially equivalent.
Because both Carney et al. and Pickering et al. use choles-
terol research as a metaphor, we should point out that other,
possibly more apposite, analogies could be drawn. For example,
consider the cautionary tale of hormone replacement therapy
(HRT). That HRT was apparently protective against cardiac
disease was demonstrated in numerous prospective observa-
tional studies. Indeed, the authors of a meta-analysis of these
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studies argued that the summary estimate protective effect, 0.5,
was such that is was unlikely to be explained by confounding
factors (9). However, when evidence from robust clinical trials
eventually became available, it indicated no reduction in cardiac
risk associated with HRT; if anything, a possible increased risk
was suggested (10,11).
This example serves to emphasize the occasional fragility of
conclusions of causality drawn from observational epidemiological
evidence and the importance of experimental data. We trust that
our editorial was never regarded as an argument against further
RCTs; it is only through these that we shall resolve the true nature
of the risk conferred by depression. However, the diagnosis and
treatment of depression in cardiac disease patients should not
depend on the outcome of such trials. Its prevalence, persistence,
and impact on quality of life should provide sufficient imperative.
Deirdre Lane, PhD
University Department of Medicine
City Hospital
Douglas Carroll, PhD
School of Sport and Exercise Science
University of Birmingham
Gregory Y. H. Lip, MD, FACC
University Department of Medicine
City Hospital
Dudley Road
Birmingham B18 7QH
United Kingdom
E-mail: g.y.h.lip@bham.ac.uk
doi:10.1016/j.jacc.2004.04.031
REFERENCES
1. Lane D, Carroll D, Lip GYH. Anxiety, depression, and prognosis
after myocardial infarction: is there a causal association? J Am Coll
Cardiol 2003;42:1808–10.
2. Wulsin LR, Singal BM. Do depressive symptoms increase the risk for
the onset of coronary disease? A systematic quantitative review.
Psychosom Med 2003;65:201–10.
3. Davey Smith G, Ebrahim S. Data dredging, bias, or confounding.
BMJ 2002;325:1437–8.
4. Macleod J, Davey Smith G. Psychosocial factors and public health: a
suitable case for treatment? J Epidemiol Comm Health 2003;57:565–
70.
5. The ENRICHD investigators. Effects of treating depression and
low perceived social support on clinical events after myocardial
infarction: the Enhancing Recovery In Coronary Heart Disease
patients (ENRICHD) randomized trial. JAMA 2003;289:3106 –
16.
6. Randomised trial of cholesterol lowering in 4444 patients with
coronary heart disease: the Scandinavian Simvastatin Survival Study
(4S). Lancet 1994;344:1383–9.
7. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol
concentrations and mortality: a quantitative review of primary preven-
tion trials. BMJ 1990;301:309–14.
8. Lane D, Lip GYH, Carroll D. Is depression following acute myocardial
infarction (AMI) an independent risk for mortality? Am J Cardiol 2004;93:
1333–4.
9. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coro-
nary heart disease: a quantitative assessment of the epidemiologic
evidence. Prev Med 1991;20:47–63.
10. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus
progestin for secondary prevention of coronary heart disease in
postmenopausal women. Heart and Estrogen/progestin Replacement
Study (HERS) research group. JAMA 1998;280:605–13.
11. Writing Group for the Women’s Health Initiative investigators. Risks
and benefits of estrogen plus progestin in healthy postmenopausal
women: principal results from the Women’s Health Initiative random-
ized controlled trial. JAMA 2002;288:321–33.
474 Letters to the Editor JACC Vol. 44, No. 2, 2004
July 21, 2004:469–74
